PE20140161A1 - Compuesto biciclico - Google Patents
Compuesto biciclicoInfo
- Publication number
- PE20140161A1 PE20140161A1 PE2013001328A PE2013001328A PE20140161A1 PE 20140161 A1 PE20140161 A1 PE 20140161A1 PE 2013001328 A PE2013001328 A PE 2013001328A PE 2013001328 A PE2013001328 A PE 2013001328A PE 20140161 A1 PE20140161 A1 PE 20140161A1
- Authority
- PE
- Peru
- Prior art keywords
- benzoxazol
- methylethyl
- acetamide
- oxy
- optionally replaced
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
SE REFIERE A COMPUESTOS BICICLICOS DE FORMULA (I) DONDE R1 ES -COR2, EN DONDE R2 ES N O UN ANILLO AROMATICO DE 5 O 6 MIEMBROS OPCIONALMENTE SUSTITUIDO; R3 ES ALQUILO(C1-C6) OPCIONALMENTE SUSTITUIDO CON HALOGENO, O CICLOALQUILO(C3-C6); R4a Y R4b SON CADA UNO H, N, ENTRE OTROS; X ES O, CO, S, SO, ENTRE OTROS; A ES UN ANILLO AROMATICO DE 5 O 6 MIEMBROS OPCIONALMENTE SUSTITUIDO; P ES UN ANILLO DE 5 MIEMBROS AROMATICO O NO AROMATICO OPCIONALMENTE SUSTITUIDO; Q ES UN ANILLO AROMATICO DE 6 MIEMBROS OPCIONALMENTE SUSTITUIDO; R6 ES ALQUILO(C1-C6) O CICLOALQUILO(C3-C6). SON COMPUESTOS PREFERIDOS: N-[(1S)-2-({6-[6-(CICLOPROPILMETOXI)-1,3-BENZOXAZOL-2-IL]PIRIDIN-3-IL}OXI)-1-METILETIL]ACETAMIDA; N-[(1S)-2-({6-[6-(CICLOPROPILMETOXI)-1,3-BENZOXAZOL-2-IL]-5-FLUOROPIRIDIN-3-IL}OXI)-1-METILETIL]ACETAMIDA; N-[(1S)-2-{[6-(6-ETOXI-1,3-BENZOXAZOL-2-IL)PIRIDIN-3-IL]OXI}-1-METILETIL]ACETAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA ACETIL-CoA CARBOXILASA SIENDO UTILES EN EL TRATAMIENTO DE OBESIDAD, DIABETES
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010266097 | 2010-11-30 | ||
JP2011175330 | 2011-08-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20140161A1 true PE20140161A1 (es) | 2014-02-19 |
Family
ID=45418740
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2013001328A PE20140161A1 (es) | 2010-11-30 | 2011-11-29 | Compuesto biciclico |
Country Status (23)
Country | Link |
---|---|
US (1) | US8729102B2 (es) |
EP (1) | EP2649062B1 (es) |
JP (1) | JP5824517B2 (es) |
KR (1) | KR20140001965A (es) |
CN (1) | CN103347872B (es) |
AR (1) | AR084032A1 (es) |
AU (1) | AU2011337565A1 (es) |
BR (1) | BR112013013417A2 (es) |
CA (1) | CA2819400A1 (es) |
CL (1) | CL2013001520A1 (es) |
CO (1) | CO6751239A2 (es) |
CR (1) | CR20130281A (es) |
DO (1) | DOP2013000118A (es) |
EA (1) | EA201390794A1 (es) |
EC (1) | ECSP13012719A (es) |
ES (1) | ES2536319T3 (es) |
MA (1) | MA34713B1 (es) |
MX (1) | MX2013006113A (es) |
PE (1) | PE20140161A1 (es) |
SG (1) | SG190925A1 (es) |
TW (1) | TW201242951A (es) |
UY (1) | UY33756A (es) |
WO (1) | WO2012074126A1 (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG185759A1 (en) | 2010-04-27 | 2012-12-28 | Takeda Pharmaceutical | Bicyclic compound derivatives and their use as acc inhibitors. |
CN103998432A (zh) | 2011-10-24 | 2014-08-20 | 武田药品工业株式会社 | 双环化合物 |
EP2928473B1 (en) * | 2012-12-07 | 2017-06-28 | Merck Sharp & Dohme Corp. | Regioselective n-2 arylation of indazoles |
PL403149A1 (pl) * | 2013-03-14 | 2014-09-15 | Celon Pharma Spółka Akcyjna | Nowe związki pochodne pirazolilobenzo[d]imidazolu |
CA2911932A1 (en) * | 2013-05-10 | 2014-11-13 | Nimbus Apollo, Inc. | Acc inhibitors and uses thereof |
JP6417403B2 (ja) | 2013-05-10 | 2018-11-07 | ギリアド アポロ, エルエルシー | Acc阻害剤及びその使用 |
JP6417401B2 (ja) | 2013-05-10 | 2018-11-07 | ギリアド アポロ, エルエルシー | Acc阻害剤及びその使用 |
JP6417402B2 (ja) | 2013-05-10 | 2018-11-07 | ギリアド アポロ, エルエルシー | Acc阻害剤及びその使用 |
EP3043800A1 (en) | 2013-09-12 | 2016-07-20 | Pfizer Inc. | Use of acetyl-coa carboxylase inhibitors for treating acne vulgaris |
IN2013MU03577A (es) | 2013-11-14 | 2015-07-31 | Cadila Healthcare Ltd | |
WO2016020288A1 (en) | 2014-08-04 | 2016-02-11 | Nuevolution A/S | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
CN104193731B (zh) * | 2014-08-27 | 2017-03-15 | 广东东阳光药业有限公司 | 一种脲取代联苯类化合物及其组合物及用途 |
SG11201701600QA (en) | 2014-08-29 | 2017-03-30 | Chdi Foundation Inc | Probes for imaging huntingtin protein |
JP2016079168A (ja) * | 2014-10-17 | 2016-05-16 | 塩野義製薬株式会社 | 9員縮合環誘導体 |
CN104447725B (zh) * | 2014-10-22 | 2018-02-02 | 浙江大学 | 一种手性含亚胺吡啶噁唑啉的化合物及其制备方法 |
WO2016130501A1 (en) | 2015-02-09 | 2016-08-18 | Incyte Corporation | Aza-heteroaryl compounds as pi3k-gamma inhibitors |
MX2018003903A (es) | 2015-09-29 | 2018-09-21 | Oncotherapy Science Inc | Compuesto biciclico y uso del mismo para inhibicion de suv39h2. |
CN105601626A (zh) * | 2015-11-04 | 2016-05-25 | 浙江大学 | 一种含2-取代噁唑啉衍生物的制备方法 |
AR106595A1 (es) | 2015-11-06 | 2018-01-31 | Incyte Corp | COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g |
US20170190689A1 (en) | 2016-01-05 | 2017-07-06 | Incyte Corporation | Pyridine and pyridimine compounds as pi3k-gamma inhibitors |
TW201803871A (zh) | 2016-06-24 | 2018-02-01 | 英塞特公司 | 作為PI3K-γ抑制劑之雜環化合物 |
SG11201909807TA (en) | 2017-04-24 | 2019-11-28 | Tesaro Inc | Methods of manufacturing of niraparib |
JP7244504B2 (ja) | 2017-10-18 | 2023-03-22 | インサイト・コーポレイション | PI3K-γ阻害剤としての三級ヒドロキシ基で置換された縮合イミダゾール誘導体 |
PT3847175T (pt) | 2018-09-05 | 2024-04-16 | Incyte Corp | Formas cristalinas de um inibidor da fosfoinositídeo 3-quinase (pi3k) |
EP4076657A1 (en) | 2019-12-20 | 2022-10-26 | Nuevolution A/S | Compounds active towards nuclear receptors |
CA3174176A1 (en) | 2020-03-31 | 2021-10-07 | Sanne Schroder Glad | Compounds active towards nuclear receptors |
MX2022012260A (es) | 2020-03-31 | 2022-11-30 | Nuevolution As | Compuestos activos frente a receptores nucleares. |
WO2023090411A1 (ja) | 2021-11-19 | 2023-05-25 | 塩野義製薬株式会社 | 心疾患または骨格筋の疾患の治療用医薬 |
WO2023217989A1 (en) | 2022-05-12 | 2023-11-16 | Syngenta Crop Protection Ag | Alkoxy heteroaryl- carboxamide or thioamide compounds |
WO2024033374A1 (en) | 2022-08-11 | 2024-02-15 | Syngenta Crop Protection Ag | Novel arylcarboxamide or arylthioamide compounds |
WO2024126650A1 (en) | 2022-12-15 | 2024-06-20 | Syngenta Crop Protection Ag | Novel bicyclic-carboxamide compounds useful as pesticides |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0862562B1 (en) | 1995-09-13 | 2001-07-04 | Takeda Chemical Industries, Ltd. | Benzoxazepine compounds, their production and use as lipid lowering agents |
ATE286395T1 (de) * | 1997-04-30 | 2005-01-15 | Lilly Co Eli | Antithrombotische mittel |
AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
DE60142961D1 (de) | 2000-04-28 | 2010-10-14 | Takeda Pharmaceutical | Antagonisten des melanin-konzentrierenden hormons |
CA2408913A1 (en) | 2000-05-16 | 2001-11-22 | Takeda Chemical Industries, Ltd. | Melanin-concentrating hormone antagonist |
WO2002006234A1 (fr) | 2000-07-17 | 2002-01-24 | Takeda Chemical Industries, Ltd. | Derives de sulfonate, procede de production et utilisation de ces derives |
DK1542997T3 (da) * | 2002-07-24 | 2012-06-25 | Dermira Canada Inc | Pyrazolylbenzothiazolderivater og deres anvendelse som terapeutiske midler |
AU2003278600A1 (en) | 2002-11-01 | 2004-05-25 | Takeda Pharmaceutical Company Limited | Agent for preventing or treating neuropathy |
AU2003277576A1 (en) | 2002-11-08 | 2004-06-07 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
AU2003284596A1 (en) | 2002-11-22 | 2004-06-18 | Takeda Pharmaceutical Company Limited | Imidazole derivative, process for producing the same, and use |
CA2527691C (en) | 2003-05-30 | 2013-01-22 | Takeda Pharmaceutical Company Limited | Condensed ring compound |
US7534887B2 (en) | 2003-09-30 | 2009-05-19 | Takeda Pharmaceutical Company Limited | Thiazoline derivative and use of the same |
US7820673B2 (en) | 2003-12-17 | 2010-10-26 | Takeda Pharmaceutical Company Limited | Urea derivative, process for producing the same, and use |
TW200523247A (en) | 2003-12-25 | 2005-07-16 | Takeda Pharmaceutical | 3-(4-benzyloxyphenyl) propanoic acid derivatives |
WO2005063725A1 (ja) | 2003-12-26 | 2005-07-14 | Takeda Pharmaceutical Company Limited | フェニルプロパン酸誘導体 |
US7786165B2 (en) | 2004-03-15 | 2010-08-31 | Takeda Pharmaceutical Company Limited | Aminophenylpropanoic acid derivative |
JP4859665B2 (ja) | 2004-03-30 | 2012-01-25 | 武田薬品工業株式会社 | アルコキシフェニルプロパン酸誘導体 |
TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
US8957070B2 (en) | 2005-04-20 | 2015-02-17 | Takeda Pharmaceutical Company Limited | Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity |
EP1911738A4 (en) | 2005-07-29 | 2009-12-16 | Takeda Pharmaceutical | PHENOXYALKANSÄUREVERBINDUNG |
US8153694B2 (en) | 2005-07-29 | 2012-04-10 | Takeda Pharmaceutical Company Limited | Cyclopropanecarboxylic acid compound |
US20080009530A1 (en) | 2005-08-10 | 2008-01-10 | Hidenori Abe | Therapeutic Agent for Diabetes |
JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
US20070219258A1 (en) * | 2006-02-15 | 2007-09-20 | Keyes Robert F | Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome |
EP2743268A3 (en) | 2006-06-27 | 2014-10-08 | Takeda Pharmaceutical Company Limited | Fused cyclic compounds as GPR40 receptor modulators |
EP2298772A1 (en) | 2006-10-18 | 2011-03-23 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
US7652133B2 (en) | 2006-10-19 | 2010-01-26 | Takeda Pharmaceutical Company Limited | Indole compound |
JPWO2008093639A1 (ja) | 2007-01-29 | 2010-05-20 | 武田薬品工業株式会社 | ピラゾール化合物 |
WO2008099794A1 (en) | 2007-02-09 | 2008-08-21 | Takeda Pharmaceutical Company Limited | Fused ring compounds as partial agonists of ppar-gamma |
EP2149550A4 (en) | 2007-04-27 | 2010-08-11 | Takeda Pharmaceutical | HETEROCYCLIC COMPOUND WITH FIVE NITROGEN CHAINS |
EP2157859A4 (en) | 2007-06-19 | 2011-01-12 | Takeda Pharmaceutical | INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE |
JP5535931B2 (ja) | 2008-10-27 | 2014-07-02 | 武田薬品工業株式会社 | 二環性化合物 |
US8927576B2 (en) * | 2009-04-06 | 2015-01-06 | PTC Therpeutics, Inc. | HCV inhibitor and therapeutic agent combinations |
SG185759A1 (en) | 2010-04-27 | 2012-12-28 | Takeda Pharmaceutical | Bicyclic compound derivatives and their use as acc inhibitors. |
WO2012108478A1 (ja) | 2011-02-09 | 2012-08-16 | 武田薬品工業株式会社 | 単環化合物 |
-
2011
- 2011-11-29 EP EP11802168.2A patent/EP2649062B1/en active Active
- 2011-11-29 EA EA201390794A patent/EA201390794A1/ru unknown
- 2011-11-29 CN CN201180066388.XA patent/CN103347872B/zh not_active Expired - Fee Related
- 2011-11-29 JP JP2013524677A patent/JP5824517B2/ja not_active Expired - Fee Related
- 2011-11-29 MX MX2013006113A patent/MX2013006113A/es not_active Application Discontinuation
- 2011-11-29 AR ARP110104436A patent/AR084032A1/es not_active Application Discontinuation
- 2011-11-29 TW TW100143674A patent/TW201242951A/zh unknown
- 2011-11-29 WO PCT/JP2011/078010 patent/WO2012074126A1/en active Application Filing
- 2011-11-29 BR BR112013013417A patent/BR112013013417A2/pt not_active IP Right Cessation
- 2011-11-29 CA CA2819400A patent/CA2819400A1/en not_active Abandoned
- 2011-11-29 UY UY0001033756A patent/UY33756A/es not_active Application Discontinuation
- 2011-11-29 US US13/306,069 patent/US8729102B2/en not_active Expired - Fee Related
- 2011-11-29 PE PE2013001328A patent/PE20140161A1/es not_active Application Discontinuation
- 2011-11-29 ES ES11802168.2T patent/ES2536319T3/es active Active
- 2011-11-29 KR KR1020137016850A patent/KR20140001965A/ko not_active Application Discontinuation
- 2011-11-29 SG SG2013041546A patent/SG190925A1/en unknown
- 2011-11-29 AU AU2011337565A patent/AU2011337565A1/en not_active Abandoned
-
2013
- 2013-05-29 CL CL2013001520A patent/CL2013001520A1/es unknown
- 2013-05-29 DO DO2013000118A patent/DOP2013000118A/es unknown
- 2013-06-05 MA MA35965A patent/MA34713B1/fr unknown
- 2013-06-11 CR CR20130281A patent/CR20130281A/es not_active Application Discontinuation
- 2013-06-24 CO CO13149620A patent/CO6751239A2/es not_active Application Discontinuation
- 2013-06-25 EC ECSP13012719 patent/ECSP13012719A/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20120142714A1 (en) | 2012-06-07 |
ES2536319T3 (es) | 2015-05-22 |
MX2013006113A (es) | 2013-11-01 |
WO2012074126A9 (en) | 2013-06-06 |
TW201242951A (en) | 2012-11-01 |
SG190925A1 (en) | 2013-07-31 |
AU2011337565A2 (en) | 2013-07-11 |
CR20130281A (es) | 2013-10-07 |
CA2819400A1 (en) | 2012-06-07 |
CN103347872B (zh) | 2014-12-24 |
AU2011337565A1 (en) | 2013-07-11 |
EP2649062A1 (en) | 2013-10-16 |
BR112013013417A2 (pt) | 2019-09-24 |
ECSP13012719A (es) | 2013-12-31 |
EP2649062B1 (en) | 2015-04-08 |
JP2013545718A (ja) | 2013-12-26 |
EA201390794A1 (ru) | 2013-11-29 |
JP5824517B2 (ja) | 2015-11-25 |
KR20140001965A (ko) | 2014-01-07 |
CL2013001520A1 (es) | 2013-10-18 |
CN103347872A (zh) | 2013-10-09 |
US8729102B2 (en) | 2014-05-20 |
WO2012074126A1 (en) | 2012-06-07 |
CO6751239A2 (es) | 2013-09-16 |
UY33756A (es) | 2012-06-29 |
AR084032A1 (es) | 2013-04-17 |
DOP2013000118A (es) | 2013-09-30 |
MA34713B1 (fr) | 2013-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20140161A1 (es) | Compuesto biciclico | |
PE20141308A1 (es) | Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a | |
PE20070136A1 (es) | COMPUESTOS DERIVADOS DE N-(PIRIDIN-2-IL)-SULFONAMIDA COMO INHIBIDORES DE LA ENZIMA 11-beta-HIDROXIESTEROIDE DESHIDROGENASA HUMANA TIPO 1 | |
PE20170004A1 (es) | Inhibidores de biaril cinasa | |
PE20110409A1 (es) | Compuestos heterociclicos antiviricos | |
PE20130235A1 (es) | Derivados de aminopirimidina como moduladores de la lrrk2 | |
PE20141307A1 (es) | Aril dihidropiridinona y piperidinona como inhibidores de monoacilglicerol aciltransferasa (mgat2) | |
PE20140934A1 (es) | Derivados de pirazol | |
PE20121506A1 (es) | Compuestos triazolopiridinas como inhibidores de c-met | |
PE20141375A1 (es) | Activadores de glucoquinasa | |
PE20130155A1 (es) | Derivados de ariletinilo | |
PE20170444A1 (es) | Herbicidas de piperidinona | |
PE20130576A1 (es) | Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10 | |
DE602005023343D1 (de) | Pyrimidinderivate als gpcr-agonisten | |
PE20141828A1 (es) | 6-alquinilo piridinas como mimeticos smac | |
PE20090884A1 (es) | Compuestos de indol como activadores de glucoquinasa | |
PE20081612A1 (es) | Analogos de las pterinas | |
PE20141540A1 (es) | Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2 | |
PE20091000A1 (es) | Inhibidores de la replicacion del virus de la inmunodeficiencia humana | |
PE20140626A1 (es) | Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona | |
PE20130647A1 (es) | Indoles | |
PE20130602A1 (es) | Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onas y su uso como inhibidores de pde9a | |
PE20140623A1 (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2 | |
PE20161444A1 (es) | 1,2-ciclopentanos sustituidos como antagonistas del receptor de orexina | |
AR064735A1 (es) | Agonistas de gpcr y composicion farmaceutica en base al compuesto |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |